This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Hematological malignancies	Heat shock protein 90 (Hsp90); janus kinase-2 (JAK-2)	A study in mice and in patient samples suggests that Hsp90 inhibitors may help treat JAK-2-dependent myeloproliferative neoplasms. In a mouse model of Jak-2-dependent myeloproliferative neoplasms, the Hsp90 inhibitor PU-H71 decreased Jak-2 levels, reduced white blood cell and platelet counts and increased survival compared with vehicle control. Next steps include investigating the efficacy of PU-H71 in animal models of additional cancers with JAK pathway activation. At least 12 companies have small molecule Hsp90 inhibitors in clinical trials for various cancers. *SciBX* 3(37); doi:10.1038/scibx.2010.1116 Published online Sept. 23, 2010	Unpatented; licensing status undisclosed	Marubayashi, S. *et al. J. Clin. Invest.*; published online Sept. 13, 2010; doi:10.1172/JCI42442 **Contact:** Ross L. Levine, Memorial Sloan-Kettering Cancer Center, New York, N.Y. e-mail: leviner@mskcc.org **Contact:** Gabriela Chiosis, same affiliation as above e-mail: chiosisg@mskcc.org **Contact:** James E. Bradner, Dana-Farber Cancer Institute, Boston, Mass. e-mail: james_Bradner@dfci.harvard.edu